Home
Nanobiotix

Nanobiotix Market Share Analysis for August 2026

Want to learn more? Reach out to the Nanobiotix team using the form.

Health > Biotechnology and Pharmaceuticals

Domainnanobiotix.com

Year Founded2003

Employees51 - 200

Annual Revenue$25M - $50M

Nanobiotix

Nanobiotix (including company regionals)

nanobiotix.com

See more website traffic and engagement information

Nanobiotix Revenue up to August 2026 is 25M - 50M

revenue generated by Nanobiotix top domains

Nanobiotix top domains revenue over 3 years

Revenue for Nanobiotix top domains

nanobiotix.com25M - 50M

See more with Sales Intelligence

Total visits to Nanobiotix's top domains

Understand Nanobiotix market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

nanobiotix.com5.5K

See more with Sales Intelligence

Avg. visit duration in Nanobiotix's top domains

Analyze Nanobiotix engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

nanobiotix.com00:00:28

See more with Sales Intelligence

Avg. pageviews on Nanobiotix's top domains

See how Nanobiotix keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

nanobiotix.com2.04

See more with Sales Intelligence

Nanobiotix top competitors by domain

Top similar sites in August 2026, ranked by their affinity

arvinas.comCompany NameArvinasEmployees201 - 500HQUnited States, Connecticut, New HavenAnnual revenue$200M - $500MTotal visits12.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Nanobiotix

These are the website technologies, by industry, used by Nanobiotix top domains

Widget (8)

Twemoji

Social (4)

Google+ Platform

Audio Video Media (3)

YouTube

Content Management System (3)

WordPress

More Technologies

9

See all

News & Signals from Nanobiotix

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNanobiotix is developing NBTXR3 on Aug 14th '26.Nanobiotix is developing NBTXR3, a cancer-treatment radioenhancer that has CE Mark approval in Europe for soft tissue sarcoma.

NewsNanobiotix SA receives financing of $100M.Nanobiotix closes USD 100m global offering to advance Nanoprimer platform.

NewsPatrick Tricoli left Nanobiotix SA on May 18th '26.Already well-established in the U.S. with a sponsored clinical trial at the University of Pittsburgh Medical Center (UPMC), the Hemerion team has recently expanded with the addition of Patrick Tricoli, formerly of Nanobiotix, as Senior Advisor for U.S. Strategy & Corporate Development, and the support of Phil Patton, a specialist in the U.S. neuro-oncology market.